symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
INZY,3.33,1.026902,672565,205559901,0,0.991-7.33,-0.02,"Inozyme Pharma, Inc.",USD,0001693011,US45790W1080,45790W108,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.inozyme.com,"Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.",Dr. Douglas A. Treco Ph.D.,Healthcare,US,56,857 330 4340,321 Summer Street,Boston,MA,02210,,0,https://financialmodelingprep.com/image-stock/INZY.png,2020-07-24,False,False,True,False,False
